We compliment Abu El Maaty et al. [1] for their meticulous investigations to assess the incidence of vitamin D deficiency in postmenopausal women at the Rheumatology outpatient clinic at the Al-Kasr Al-Aini Medical University Hospital at New Cairo City, Egypt, and concur that randomised control trials are desirable to decide the dose schedules for vitamin D supplementation in postmenopausal women. Nevertheless, it would also be important to carry out comparable investigations at different non-academic, non-research health care centres in different Egyptian regions.
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Although all vitamin D estimations (as serum 25-hydroxyvitamin D) at the Al-Kasr Al-Aini Medical University Hospital were carried out employing the 'gold standard' technology of high-performance liquid chromatography method (HPLC), not many hospital or health care centres elsewhere would be equipped to carry out HPLC in their premises. They would have to employ commercially available enzyme-linked immunosorbent assay (ELISA) kits for serum 25-hydroxyvitamin D measurements. A beginning towards an in-house standardisation could be made in individual laboratories by picking up blood samples from cases with a high or level serum 25-hydroxyvitamin D level and to prepare its 20 aliquots. By testing such aliquots repeatedly, it would be possible to work out local mean serum 25-hydroxyvitamin D level and standard deviation (SD) [2] .
Vitamin D deficiency is a global phenomenon afflicts about one billion people worldwide [3] . In resource-poor countries, with vast population of masses with vitamin D deficiency, the laboratory infrastructure is poor [4] and it would not be feasible to assay vitamin D level even by ELISA technology. Simpler, point-of-care, rapid tests are needed to quantify 25-hydroxyvitamin D level levels in the clinicians' premises and in laboratory setup at primary health care centre laboratories.
Last but not least, future plans towards vitamin D supplementation in postmenopausal women in Egypt [1] should include both vitamin D3 supplementation and a watch on post-supplementation vitamin D3 levels. A daily supplementation of 1,000 IU of vitamin D3 may fail to bring levels to a minimum of 75 nmol/l in 20-30 % cases [5] .
